|
|
Post by lakers on Apr 13, 2016 1:17:03 GMT -5
|
|
|
|
Post by peppy on Apr 13, 2016 1:35:38 GMT -5
I do not think what is happening with price has anything to do with the conference call. I think it is a news leak. The volume coming in.
Price may have to do with MNKD has money..... and the plan is to market Afrezza. same bat label same bat channel
Competitive price. Better insurance coverage. Physicians that will prescribe it rather than say.... no. With the exception of proboard physicians, Physician understanding and knowledge of Afrezza seems poor. The statements I have read, the physicians equating Afrezza with exubera when asked. The physicians not making the distinction, Exubera was a hexamer and afrezza is a monomeric insulin. Also, the physicians are not seeing the phase 1, large insulin hit to the liver, as stopping gluconeogenesis. Nothing can be said. hexamer and monomer is a fact that can be talked about.
It's a news leak. Did you see price on the way down? The stories told, slow launch my assets. Price may have to do with MNKD plan, money and RLS. the rest, is baloney. IMO.
|
|
|
|
Post by mnholdem on Apr 13, 2016 7:22:54 GMT -5
This article link was already posted yesterday (see "This stock analyst article blames Sanofi "thread ).
|
|
